Abstract:The p53 tumor suppressor gene plays a key role in prevention of tumor formation through transcriptional dependent and independent mechanisms. Transcriptional-dependent mechanisms are mainly mediated by p53 regulation of downstream targets, leading to growth arrest and apoptosis. Mutational inactivation of the p53 gene is detected in more than 50% of human cancers. Mutation of p53 renders cancer cells more resistant to current cancer therapies due to lack of p53-mediated apoptosis. Extensive studies have been conducted to identify small molecules that manipulate p53, including restoration of mutant p53 conformation to wild-type, disruption of murine double minute-2 (Mdm2)-p53 binding to increase p53 level and inhibition of Mdm2 E3 ubiquitin ligase activity to prevent p53 degradation. Another approach was to identify and validate "drugable" target(s) in p53 signaling pathways that modulate p53-induced apoptosis. We profiled a p53 temperature-sensitive lung cancer cell model with the Affymetrix human HG-U133 GeneChip, covering the entire human transcriptome. We identified thousands of unique genes that were either induced or repressed in response to p53-induced apoptosis. A follow-up study characterized a p53-repressed gene, SAK, a polo-like kinase (PLK) family member, as an appealing cancer drug target. Snk/Plk-akin kinase (SAK) silencing via small interfering RNA (siRNA) induced apoptosis, whereas SAK overexpression attenuated p53-induced apoptosis. Thus, SAK repression by p53 contributes to p53-induced apoptosis. Future work is directed at determining the normal cell response to SAK silencing. If a therapeutic window is obtained, a SAK inhibitor identified from high throughput screening (HTS) could serve as a lead compound for development of a novel class of apoptosis-inducing anticancer drugs.

Down-regulated P53 by Sirna Increases Smad4's Activity in Promoting Cell Apoptosis in MCF-7 Cells.

Effect of Microrna-34a in Cell Cycle, Differentiation, and Apoptosis: A Review

Silencing of Mutant P53 by Sirna Induces Cell Cycle Arrest and Apoptosis in Human Bladder Cancer Cells

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

RNA Interference Targeting Mutant P53 Inhibits Growth and Induces Apoptosis in DU145 Human Prostate Cancer Cells

Down-regulation of Smad4 Enhances Proliferation and Invasion of Colorectal Carcinoma HCT116 Cells and Up-Regulates Id2

MicroRNA Expression Profiling of Pancreatic Cancer Cell Line L3.6p1 Following B7-H4 Knockdown

Microrna-34a induces a senescence-like change via the down-regulation of SIRT1 and up-regulation of p53 protein in human esophageal squamous cancer cells with a wild-type p53 gene background.

MicroRNA-449a inhibits cell proliferation and migration by regulating mutant p53 in MDA-MB-468 cells

Involvement of miR-605 and miR-34a in the DNA damage response promotes apoptosis induction.

Inactivation of Oncogenic Camp-Specific Phosphodiesterase 4D by Mir-139-5p in Response to P53 Activation

P53 and Its Downstream Proteins As Molecular Targets of Cancer

Downregulation of Wild-Type P53 Protein by HER-2/neu Mediated PI3K Pathway Activation in Human Breast Cancer Cells: Its Effect on Cell Proliferation and Implication for Therapy

Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway

Overexpression of SMAR1 Enhances Radiosensitivity in Human Breast Cancer Cell Line MCF7 Via Activation of P53 Signaling Pathway.

USP7 facilitates SMAD3 autoregulation to repress cancer progression in p53-deficient lung cancer

p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target

Synergistic Suppression of Prostatic Cancer Cells by Coexpression of Both Murine Double Minute 2 Small Interfering RNA and Wild-Type p53 Gene In Vitro and In Vivo

Knockdown of SMAD3 Inhibits the Growth and Enhances the Radiosensitivity of Lung Adenocarcinoma Via P21 in Vitro and in Vivo.

Expression of P53 in Breast Cancer and Regulatory Effects of 5-Aza-2′-deoxycytidine on P53